Abstract
Regardless of the degree of glycemic control, Linagliptin (LINA) has lower hypoglycemia risk than all doses of Glimepiride (GLIM), at all timeg points over a 2-year trial
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
